Aura Biosciences/$AURA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aura Biosciences
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Ticker
$AURA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
108
ISIN
US05153U1079
Website
Aura Biosciences Metrics
BasicAdvanced
$382M
-
-$1.90
0.43
-
Price and volume
Market cap
$382M
Beta
0.43
52-week high
$11.39
52-week low
$4.35
Average daily volume
219K
Financial strength
Current ratio
11.06
Quick ratio
10.523
Long term debt to equity
11.934
Total debt to equity
14.413
Profitability
EBITDA (TTM)
-101.63
Effective tax rate (TTM)
-0.09%
Management effectiveness
Return on assets (TTM)
-32.92%
Return on equity (TTM)
-56.24%
Valuation
Price to book
2.42
Price to tangible book (TTM)
2.42
Price to free cash flow (TTM)
-3.833
Free cash flow yield (TTM)
-26.09%
Free cash flow per share (TTM)
-160.70%
Growth
Earnings per share change (TTM)
2.81%
3-year earnings per share growth (CAGR)
-22.65%
What the Analysts think about Aura Biosciences
Analyst ratings (Buy, Hold, Sell) for Aura Biosciences stock.
Bulls say / Bears say
Aura Biosciences' lead candidate, bel-sar, demonstrated significant efficacy in early-stage choroidal melanoma, with over 220 patients pre-screened for the global Phase 3 CoMpass trial, indicating strong clinical progress. (stocktitan.net)
The company reported a robust cash position of $128 million as of Q1 2025, expected to fund operations into the second half of 2026, providing financial stability for ongoing research and development. (stocktitan.net)
Institutional investors, including Price T Rowe Associates Inc. MD, increased their holdings in Aura Biosciences by 7.9% in Q4 2024, reflecting growing confidence in the company's prospects. (marketbeat.com)
Aura Biosciences reported a net loss of $27.48 million in Q1 2025, with an adjusted loss per share of 55 cents, missing analyst expectations and indicating ongoing financial challenges. (tradingview.com)
The company's stock price has experienced volatility, with a 28% decline year-to-date as of May 2025, potentially reflecting investor concerns over financial performance and market conditions. (tradingview.com)
Insider selling activity, including the sale of 11,822 shares by insider Janet Jill Hopkins in November 2024, may raise questions about internal confidence in the company's future performance. (defenseworld.net)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
Aura Biosciences Financial Performance
Revenues and expenses
Aura Biosciences Earnings Performance
Company profitability
Aura Biosciences News
AllArticlesVideos
Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants
GlobeNewsWire·2 months ago
Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants
GlobeNewsWire·2 months ago
Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aura Biosciences stock?
Aura Biosciences (AURA) has a market cap of $382M as of July 08, 2025.
What is the P/E ratio for Aura Biosciences stock?
The price to earnings (P/E) ratio for Aura Biosciences (AURA) stock is 0 as of July 08, 2025.
Does Aura Biosciences stock pay dividends?
No, Aura Biosciences (AURA) stock does not pay dividends to its shareholders as of July 08, 2025.
When is the next Aura Biosciences dividend payment date?
Aura Biosciences (AURA) stock does not pay dividends to its shareholders.
What is the beta indicator for Aura Biosciences?
Aura Biosciences (AURA) has a beta rating of 0.43. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.